Price
Financials
Standalone, Rs crore| Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.70 | 9.54 | 39.51 | 21.25 | 11.73 | 11.59 | 29.91 | 26.84 | 63.05 | 11.10 |
| Expenses | 20.15 | 6.48 | 37.10 | 19.90 | 10.35 | 9.66 | 27.00 | 23.49 | 59.54 | 9.01 |
| Operating Profit | 1.55 | 3.06 | 2.41 | 1.35 | 1.38 | 1.93 | 2.91 | 3.35 | 3.51 | 2.09 |
| OPM % | 7.14% | 32.08% | 6.10% | 6.35% | 11.76% | 16.65% | 9.73% | 12.48% | 5.57% | 18.83% |
| Other Income | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.04 | 0.02 |
| Interest | 0.09 | 0.26 | 0.27 | 0.20 | 0.33 | 0.24 | 0.44 | 0.38 | 1.03 | 0.30 |
| Depreciation | 0.11 | 0.24 | 0.24 | 0.16 | 0.36 | 0.26 | 0.27 | 0.27 | 0.27 | 0.32 |
| Profit before tax | 1.37 | 2.56 | 1.90 | 0.99 | 0.69 | 1.43 | 2.21 | 2.71 | 2.25 | 1.49 |
| Tax % | 13.14% | 25.39% | 23.16% | 25.25% | 86.96% | 48.25% | 10.86% | 25.09% | 26.22% | 25.50% |
| Net Profit | 1.19 | 1.91 | 1.45 | 0.74 | 0.08 | 0.75 | 1.97 | 2.02 | 1.66 | 1.11 |
| EPS in Rs | 0.18 | 0.29 | 0.22 | 0.11 | 0.01 | 0.11 | 0.30 | 0.31 | 0.25 | 0.17 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 32 | 30 | 33 | 34 | 43 | 47 | 82 | 131 | 131 |
| Expenses | 30 | 28 | 31 | 28 | 39 | 42 | 74 | 120 | 119 |
| Operating Profit | 1 | 2 | 2 | 5 | 4 | 5 | 8 | 12 | 12 |
| OPM % | 4.2% | 6% | 7% | 16% | 9% | 10% | 10% | 9% | 9% |
| Other Income | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 1 | 4 | 4 | 4 | 6 | 9 | 9 |
| Tax % | 28% | 29% | 27% | 26% | 25% | 13% | 32% | 26% | |
| Net Profit | 0 | 0 | 1 | 3 | 3 | 3 | 4 | 6 | 7 |
| EPS in Rs | 1.25 | 1.50 | 1.50 | 0.59 | 0.43 | 0.50 | 0.63 | 0.97 | 1.03 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 8% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 32% | 45% | 56% | ||
| Compounded Profit Growth | % | 64% | 32% | 124% | ||
| Stock Price CAGR | % | % | -11% | -15% | ||
| Return on Equity | % | 13% | 12% | 15% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.42 | 0.42 | 0.50 | 8 | 11 | 11 | 33 | 33 |
| Reserves | 5 | 5 | 6 | 3 | 21 | 25 | 6 | 13 |
| Borrowings | 8 | 9 | 17 | 16 | 7 | 6 | 11 | 22 |
| Other Liabilities | 3 | 10 | 5 | 21 | 10 | 15 | 22 | 39 |
| Total Liabilities | 16 | 24 | 29 | 48 | 49 | 57 | 72 | 106 |
| Fixed Assets | 2 | 5 | 6 | 7 | 7 | 12 | 12 | 15 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 14 | 19 | 23 | 41 | 42 | 44 | 60 | 92 |
| Total Assets | 16 | 24 | 29 | 48 | 49 | 57 | 72 | 106 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -3 | 3 | -6 | 2 | -9 | 8 | -4 | -4 |
| Cash from Investing Activity | -1 | -3 | -2 | -1 | 1 | -6 | -0 | -4 |
| Cash from Financing Activity | 4 | -0 | 7 | -1 | 8 | -2 | 4 | 9 |
| Net Cash Flow | 0 | 0 | -0 | 0 | -0 | -0 | 0 | 1 |
| Free Cash Flow | -4 | 0 | -8 | 1 | -9 | 2 | -4 | -8 |
| CFO/OP | -225% | 177% | -268% | 41% | -206% | 185% | -31% | -37% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 111 | 153 | 132 | 215 | 192 | 197 | 155 | 148 |
| Inventory Days | 21 | 52 | 72 | 212 | 130 | 149 | 128 | 110 |
| Days Payable | 18 | 122 | 58 | 218 | 76 | 92 | 98 | 93 |
| Cash Conversion Cycle | 115 | 83 | 146 | 208 | 246 | 254 | 186 | 165 |
| Working Capital Days | 62 | 7 | 74 | 117 | 221 | 181 | 124 | 103 |
| ROCE % | 12% | 10% | 23% | 15% | 11% | 16% | 18% |
| Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% |
| Public | 32.53% | 32.53% | 32.54% | 32.53% | 32.53% | 32.53% | 32.53% | 32.53% | 32.53% | 32.53% | 32.53% | 32.53% |
| No. of Shareholders | 978 | 921 | 873 | 832 | 825 | 966 | 997 | 1,008 | 998 | 991 | 971 | 943 |
Fundamentals
Market Cap₹ 32.7 Cr.
Current Price₹ 9.90
Stock P/E4.83
Book Value₹ 6.95
ROCE18.2 %
ROE15.0 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)56%
Compounded Profit Growth (TTM)124%
Standalone figures.
Valuation
Market capRs 33 Cr
Enterprise valueRs 39 Cr
P/E (TTM)4.88x
Price to book0.93x
Price to sales0.25x
EV / EBITDA3.24x
EV / EBIT3.58x
EV / sales0.30x
Price to cash flow3.95x
Earnings yield20.48%
Dividend yield0.85%
P/E, 3-year average4.13x
P/B, 3-year average0.37x
P/E, 5-year average4.13x
P/B, 5-year average0.37x
Profitability
Operating margin (excl. other income)9.77%
Operating margin (incl. other income)10.89%
EBITDA margin9.12%
Pre-tax margin6.62%
Net profit margin5.16%
Net margin, latest quarter10.00%
ROE9.76%
ROCE11.47%
ROA6.26%
ROE, 3-year average17.86%
ROCE, 3-year average16.67%
ROA, 3-year average6.44%
ROE, 5-year average13.87%
ROCE, 5-year average14.40%
ROA, 5-year average4.62%
ROIC (approx.)22.76%
Tax rate13.16%
Other income / net worth1.46%
Growth
Sales growth (latest year)8.69%
Profit growth (latest year)17.79%
Sales CAGR, 3 years12.41%
Sales CAGR, 5 years7.93%
Profit CAGR, 3 years83.01%
Profit CAGR, 5 years61.64%
Sales growth QoQ-82.39%
Profit growth QoQ-33.13%
Sales growth YoY (latest quarter)-4.23%
Profit growth YoY (latest quarter)48.00%
Per share
EPS (TTM)Rs 2.05
EPS (latest year)Rs 3.01
EPS (latest quarter)Rs 0.34
EPS, 3-year averageRs 3.02
EPS, 5-year averageRs 5.69
Book value per shareRs 10.78
Sales per shareRs 39.67
Cash flow per shareRs 2.53
Free cash flow per shareRs -2.42
Dividend per share (latest year)Rs 0.25
Dividend per share, 3-year averageRs 0.25
Dividend per share, 5-year averageRs 0.25
Dividends
Dividend payout8.46%
Dividend payout, 3-year average8.46%
Dividend payout, 5-year average8.46%
Efficiency
Asset turnover0.82x
Fixed asset turnover3.73x
Inventory turnover2.49x
Inventory days146 days
Debtor days197 days
Debtors turnover1.85x
Creditor days93 days
Cash conversion cycle165 days
Working capital days103 days
Leverage
Total debtRs 6 Cr
Cash and bankRs 0 Cr
Net debtRs 6 Cr
Debt to equity0.16x
Net debt / EBITDA0.47x
Interest coverage5.03x
Owners' fund to total sources62.82%
Debt to assets10.05%
Cash flow
Cash from Operating Activity (latest year)Rs 8 Cr
Cash from Investing Activity (latest year)Rs -6 Cr
Cash from Financing Activity (latest year)Rs -2 Cr
Net Cash Flow (latest year)Rs -0 Cr
Free cash flow (latest year)Rs -8 Cr
FCFE (approx.: FCF + change in debt)Rs -9 Cr
Cash from ops / profit, 5 years-0.37x
Sales to cash flow5.57x
Statement figures
Net sales (TTM)Rs 131 Cr
Net sales (latest year)Rs 47 Cr
Sales (latest quarter)Rs 11 Cr
Operating profit excl. other income (latest year)Rs 5 Cr
Operating profit (latest quarter)Rs 2 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 12 Cr
PBDT (TTM)Rs 10 Cr
Profit before tax (TTM)Rs 9 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs 7 Cr
Net profit (latest year)Rs 3 Cr
Net profit (latest quarter)Rs 1 Cr
Depreciation (TTM)Rs 1 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 2 Cr
Cost of goods sold (latest year)Rs 39 Cr
Total expenditure (latest year)Rs 42 Cr
Total income (latest year)Rs 47 Cr
Share capitalRs 11 Cr
ReservesRs 25 Cr
Shareholders' fundsRs 36 Cr
Total assetsRs 57 Cr
Net blockRs 12 Cr
ReceivablesRs 25 Cr
InventoryRs 16 Cr
Other liabilitiesRs 15 Cr
Shares outstanding (crore)3.30
Ownership
Promoter holding67.47% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 4.9 is at the 4th percentile of its own 3.9-year range
(median 26.1, low 4.6, high 366.7).
P/B 0.93 is at the 6th percentile (median 8.99).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | JFLLIFE | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +1.0% | -2.8% | +3.8 pts |
| 1 month | -8.3% | -6.8% | -1.5 pts |
| 3 months | +5.8% | -7.6% | +13.4 pts |
| 6 months | -8.7% | +0.4% | -9.1 pts |
| 1 year | -36.7% | -9.9% | -26.8 pts |
| 2 years | -78.3% | -13.6% | -64.7 pts |
| 3 years | -78.7% | +14.2% | -92.9 pts |
Red flags
F-score 7 of 8| explain | Weak cash conversion Cash from operations was 18% of net profit over the last 3 years |
| explain | Share dilution Share count up 0% in a year, 1733% in three |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹11 Cr -4.2% vs Jun 2025.
Net profit ₹1 Cr +48.0%.
Against our estimate for Jun 2026: sales -40.1%, profit -8.3% in line. Our estimate for Sep 2026: sales Rs 48 Cr, profit Rs 3 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Less than 100 unique PAN traded in previous 30 daysMandatory Market making period in SME scrip is overSME scrip is not regularly traded
Quick answers
What is the market cap of JFL Life Sciences Ltd?
JFL Life Sciences Ltd (JFLLIFE) has a market capitalisation of Rs 32.7 Cr. at the 2026-10-01 close.
What is the P/E ratio of JFL Life Sciences Ltd?
JFL Life Sciences Ltd trades at a P/E of 4.83 on trailing twelve-month profit, at the 2026-10-01 close.
What were JFL Life Sciences Ltd's latest quarterly results?
In the Jun 2026 quarter, JFL Life Sciences Ltd sales was Rs 11 Cr (-4.2% vs Jun 2025) and net profit was Rs 1 Cr.
What is the 52-week high and low of JFL Life Sciences Ltd?
The 52-week high is Rs 14.67 and the 52-week low is Rs 8.55.